Parkinson's disease in Nepal: Symptoms, Causes & Treatment | aihealz
ICD variantParkinson's disease is a specific ICD-10 coded subtype of Parkinson's Disease. The clinical content below covers Parkinson's Disease in general.
NeurologysevereICD-10 · G20
Parkinson's disease.Care & specialists in Nepal
In Nepal, parkinson's disease is managed by neurologists. Parkinson's disease is a progressive neurodegenerative disorder in which dopamine-producing neurons in the substantia nigra of the midbrain die off and abnormal alpha-synuclein protein accumulates as Lewy bodies. Roughly 1% of adults over 60 and up to 4% of adults over 80 develop the disease, and global cases exceeded 8.5 million in 2019 — more than double the figure from 1990 (GBD 2019).
aliases · Parkinson's Disease (PD, paralysis agitans)· Kampavata· पार्किंसन रोग (Parkinson Rog)· Maladie de Parkinson· reviewed May 12, 2026
EB
Reviewed by AIHealz Medical Editorial Board · NeurologyLast reviewed May 12, 2026
Parkinson's disease (ICD-10: G20) is a progressive neurodegenerative disorder defined pathologically by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and the accumulation of misfolded alpha-synuclein protein as intracellular Lewy bodies and Lewy neurites. The disease is the second most common neurodegenerative condition after Alzheimer's disease and the most common movement disorder in adults. Motor symptoms become clinically apparent only after roughly 50-70% of nigral dopaminergic neurons have already been lost and striatal dopamine is depleted by more than 60%, which is why the disease is often well advanced at diagnosis. Pathology is not limited to the substantia nigra: alpha-synuclein deposition begins in the olfactory bulb and lower brainstem (Braak stages 1-2), spreads to the midbrain and limbic system (stages 3-4), and reaches the neocortex in advanced disease (stages 5-6), which corresponds to the gradual emergence of cognitive and autonomic features.
key facts
Prevalence
1% of adults over 60; 4% of adults over 80 (Pringsheim 2014 meta-analysis); ~1 million people in the US (Parkinson's Foundation 2022)
Demographics
Men affected 1.4-2.0x more often than women across most populations
Avg. age
Mean motor onset age 60-65; ~10% of cases present before age 50 (young-onset Parkinson's)
Global cases
8.5 million worldwide in 2019, projected to exceed 13 million by 2040 (GBD 2019)
Specialist
Neurology
§ 02
How you might notice it
The key symptoms of Parkinson's disease are: Resting tremor at 4-6 Hz, classically a unilateral 'pill-rolling' tremor of the thumb and fingers that disappears with voluntary movement and worsens with stress — present in roughly 70% of patients at diagnosis., Bradykinesia, the cardinal slowing of voluntary movement, observed as small handwriting (micrographia), reduced arm swing on the affected side, shuffling steps, and a masked facial expression with reduced blinking., Rigidity with a 'cogwheel' or 'lead-pipe' quality felt on passive movement of the wrist or elbow, often accompanied by aching shoulder pain that can be misdiagnosed as frozen shoulder for months before tremor appears., Postural instability emerging after several years of disease, producing a stooped posture, festinating gait, and recurrent falls — a major driver of fracture and hospitalization in advanced disease., Gait freezing, in which the feet feel momentarily glued to the floor especially when starting to walk, turning, or passing through a doorway; freezing is a leading cause of falls and loses responsiveness to levodopa over time., Hypophonia and dysarthria, with a soft, monotone, slurred voice that the patient often perceives as normal while listeners struggle to hear — present in over 80% of patients within 5 years of diagnosis., Reduced sense of smell (hyposmia or anosmia), which precedes motor symptoms by 5-10 years in many patients and is now one of the most reliable prodromal markers..
01Resting tremor at 4-6 Hz, classically a unilateral 'pill-rolling' tremor of the thumb and fingers that disappears with voluntary movement and worsens with stress — present in roughly 70% of patients at diagnosis.
02Bradykinesia, the cardinal slowing of voluntary movement, observed as small handwriting (micrographia), reduced arm swing on the affected side, shuffling steps, and a masked facial expression with reduced blinking.
03
§ 03
How it’s diagnosed
diagnosis
Diagnosis of Parkinson's disease is clinical. The current standard is the Movement Disorder Society 2015 Clinical Diagnostic Criteria (Postuma 2015), which require the core motor syndrome of bradykinesia plus either rest tremor or rigidity, in combination with at least two supportive features (clear and dramatic response to levodopa, levodopa-induced dyskinesia, classical rest tremor, or olfactory loss / cardiac sympathetic denervation on MIBG scan), and the absence of any absolute exclusion criteria or red flags. The diagnostic workup begins with a detailed history that probes prodromal features — anosmia, RBD, constipation, depression — and a thorough neurological exam, particularly the MDS-UPDRS motor section. Brain MRI is recommended in essentially all new diagnoses, primarily to rule out vascular parkinsonism, normal-pressure hydrocephalus, and atypical parkinsonian syndromes; it is normal in classical Parkinson's. DaT-SPECT imaging (123I-FP-CIT, marketed as DaTscan) shows reduced striatal dopamine transporter binding and helps distinguish Parkinson's from essential tremor, drug-induced parkinsonism, and psychogenic tremor when the clinical picture is ambiguous; it does not separate Parkinson's from atypical parkinsonism. Response to a levodopa trial — at least 30% improvement on the MDS-UPDRS motor score with an adequate dose — is itself a supportive criterion. Genetic testing is offered selectively for young-onset disease, strong family history, or relevant ancestry (LRRK2, GBA panels). Skin biopsy for phosphorylated alpha-synuclein and seed amplification assays (RT-QuIC) on cerebrospinal fluid are increasingly available and approach 90% sensitivity in research settings. The AAN 2019 evaluation guideline emphasises serial reassessment over time, since the diagnosis is most reliably confirmed at follow-up two years later when atypical features have either appeared or stayed absent.
Key tests
01
Clinical examination with MDS-UPDRS motor scoringThe reference standard. Confirms the cardinal features (bradykinesia, rest tremor, rigidity, postural instability), grades severity, and tracks response to treatment over time.
02
§ 04
Treatment & cost
medical treatments
✓Carbidopa-levodopa (immediate-release, controlled-release, or extended-release; typical 300-1000 mg levodopa/day in divided doses)
✓Dopamine agonists (pramipexole 0.125-1.5 mg three times daily; ropinirole 0.25-8 mg three times daily; rotigotine transdermal patch 2-16 mg/24h)
✓COMT inhibitors (entacapone 200 mg with each levodopa dose; opicapone 50 mg once daily)
surgical options
Subthalamic nucleus deep brain stimulation (STN-DBS)Roughly 50% improvement in off-medication motor scores and a 4-5 hour/day reduction in off-time in randomized trials; quality-of-life benefit sustained for at least 10 years in long-term follow-up.
Globus pallidus internus deep brain stimulation (GPi-DBS)Roughly 35-45% improvement in off-medication motor scores; similar long-term motor benefit to STN-DBS in head-to-head trials (CSP 468).
MR-guided focused ultrasound thalamotomy (Vim-FUS)Roughly 60-70% reduction in tremor severity at 12 months in the unilaterally treated hand (Bond 2017).
Levodopa-carbidopa intestinal gel (LCIG / Duopa) via PEG-J pumpReduces off-time by roughly 4 hours/day with improved quality of life in advanced motor fluctuations (Olanow 2014).
§ 05
Causes & risk factors
known causes
Loss of dopaminergic neurons in the substantia nigra
The defining cellular event. Pigmented neurons in the pars compacta progressively die, depleting dopamine in the striatum and disrupting the basal-ganglia circuits that fine-tune voluntary movement. Symptoms appear after roughly 50-70% of these neurons have already been lost.
Soluble alpha-synuclein protein adopts an abnormal beta-sheet structure, forms fibrils, and accumulates as Lewy bodies and Lewy neurites. The pathology spreads in a stereotyped pattern (Braak staging) from the lower brainstem and olfactory bulb upward to the cortex, paralleling the clinical course.
Genetic mutations (monogenic and risk variants)
Autosomal dominant mutations in LRRK2 and SNCA, recessive mutations in Parkin (PARK2), PINK1, and DJ-1, and the strong risk variant GBA (glucocerebrosidase) account together for an estimated 5-10% of cases. GBA carriers have roughly 5-fold increased risk and faster cognitive decline (Sidransky 2009).
Mitochondrial dysfunction and oxidative stress
Complex I deficiency in substantia nigra neurons, impaired mitophagy via PINK1/Parkin, and accumulation of reactive oxygen species damage dopaminergic neurons. The MPTP toxin (which causes parkinsonism via Complex I inhibition) confirmed this mechanism experimentally in the 1980s.
Environmental exposures
Chronic exposure to pesticides (rotenone, paraquat), industrial solvents (trichloroethylene), and well-water from agricultural areas raises risk. Rural living and farming occupations are associated with 1.5-2x higher incidence in multiple cohort studies.
Gut-brain axis and enteric alpha-synuclein
Alpha-synuclein pathology is detected in the enteric nervous system years before brain involvement in many patients. Vagotomy reduces later Parkinson's risk in cohort studies (Svensson 2015), and gut microbiome alterations are now active research targets.
§ 06
Living with it
01Maintain regular moderate-to-vigorous physical activity throughout adult life — cohort data show a roughly 30% lower Parkinson's risk in the most active quartile
02Avoid occupational and residential exposure to known pesticides where feasible; use protective equipment in agricultural and industrial settings
03Seek prompt evaluation for REM sleep behaviour disorder — randomised prevention trials are beginning to recruit prodromal patients
04Address chronic constipation, depression, and anosmia early; while they do not prevent disease, they bring patients into the diagnostic pathway sooner
05Avoid recurrent head trauma — wear seatbelts and appropriate sport helmets; manage falls risk in older adults
recommended foods
•Mediterranean-style diet rich in vegetables, fruits, whole grains, fish, and olive oil — observational data support lower Parkinson's incidence and slower progression
•Adequate fibre (25-35 g/day) and 1.5-2 litres of fluid daily to manage constipation, a common and bothersome non-motor symptom
•Coffee or caffeinated tea in moderate amounts, unless contraindicated — consistent association with lower disease incidence
§ 07
When to seek help
why see a neurology
A movement-disorder neurologist should evaluate any suspected new diagnosis to confirm Parkinson's, exclude atypical parkinsonian syndromes, and structure long-term care. Specialist input is also needed at every transition: when motor fluctuations or dyskinesias emerge, when cognitive or psychiatric symptoms appear, when assessing eligibility for DBS or focused ultrasound, and when planning end-of-life care. Population studies show that Parkinson's patients followed by a neurologist have lower mortality and lower nursing-home placement rates than those followed only in primary care (Willis 2011).
01Falls and fractures from postural instability and gait freezing — hip fracture rates are 2-3x higher than in age-matched controls and a major driver of hospitalization and mortality
02Parkinson's disease dementia, with cumulative incidence approaching 80% over 20 years of disease; managed with rivastigmine and supportive care
03Aspiration pneumonia from progressive dysphagia and reduced cough reflex — the leading cause of death in advanced Parkinson's
04Parkinson's disease psychosis, including visual hallucinations and delusions, affecting up to 50% over 10-20 years; can be triggered or worsened by dopaminergic medication, infection, or delirium
05Severe orthostatic hypotension and autonomic failure, producing syncope, falls, and reduced quality of life; pronounced autonomic failure early in the disease should prompt re-evaluation for multiple system atrophy
Tremor-predominant Parkinson's diseaseResting tremor dominates the clinical picture with relatively preserved postural reflexes and slower cognitive decline. Roughly 30-40% of patients; long-term prognosis is generally better than the akinetic-rigid subtype.
Postural-instability gait-disorder (PIGD) / akinetic-rigid Parkinson'sBradykinesia, rigidity, gait freezing, and postural instability dominate; tremor is mild or absent. Cognitive decline and falls accumulate faster, and response to levodopa is less complete.
Young-onset Parkinson's disease (YOPD)Onset before age 50; accounts for about 10% of cases. More commonly linked to monogenic causes (LRRK2, PARK2/Parkin, PINK1, GBA). Disease progression is slower but levodopa-induced dyskinesias appear sooner.
Genetic Parkinson's disease (monogenic forms)Mutations in LRRK2, GBA, SNCA, Parkin, PINK1, and DJ-1 account for ~5-10% of all cases overall but a higher share of YOPD. GBA carriers in particular have faster cognitive decline.
Atypical and secondary parkinsonism (differential)Multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, vascular parkinsonism, and drug-induced parkinsonism mimic Parkinson's but progress differently and respond poorly to levodopa. Distinguishing these is the core diagnostic task.
Living with Parkinson's disease
Timeline
Parkinson's is a chronic progressive disease rather than one with recovery. After starting levodopa, most patients experience a clear motor improvement within days to a few weeks, with peak benefit reached at 4-8 weeks once doses are titrated. The first 3-5 years are often referred to as the 'honeymoon period' of stable response. Motor fluctuations and dyskinesias typically appear 5-10 years after starting levodopa. Following STN-DBS, motor improvement is apparent in the days after activation and continues to be optimised over the first 6-12 months as stimulation settings are refined and medication is reduced.
Lifestyle
01Exercise vigorously 3-5 times per week, combining aerobic (treadmill, cycling), resistance, balance, and flexibility work — slows symptom progression and reduces falls
02Schedule levodopa doses around meals — high-protein meals can blunt absorption, so take medication 30-45 minutes before or 1-2 hours after protein-rich meals
03Use cueing strategies — visual lines on the floor, metronome apps, or counting aloud — to overcome gait freezing
04Practice loud-voice training (LSVT-LOUD) to slow hypophonia and dysarthria progression
05Home-proof against falls: remove loose rugs, add grab bars, improve lighting, and consider a walking aid before falls happen
06Manage orthostatic hypotension with adequate salt and fluid intake, compression stockings, and slow positional changes; avoid antihypertensives that drop standing blood pressure
07
Complementary approaches
Tai chi for balance and falls preventionRandomised trial of 195 patients (Li 2012, NEJM) showed tai chi significantly reduced falls and improved postural stability versus resistance training and stretching over 6 months. Now incorporated into many Parkinson's exercise programs.
High-intensity treadmill or cycling exerciseSPARX (Schenkman 2018, JAMA Neurology) showed high-intensity treadmill training at 80-85% maximum heart rate slowed MDS-UPDRS motor progression at 6 months. Supports an exercise prescription, not as a replacement for medical therapy.
Coffee and caffeine intakeCohort studies (Honolulu-Asia Aging Study; NHS/HPFS) consistently link regular coffee consumption with 30-40% lower Parkinson's incidence. Causation is unproven and the effect on established disease is modest at best, but moderate coffee is reasonable for most patients.
Choosing a doctor
Look for board certification in neurology with a fellowship or substantial practice focus in movement disorders, regular use of the MDS-UPDRS, comfort interpreting DaT-SPECT, access to multidisciplinary rehabilitation (physiotherapy, occupational therapy, speech and language therapy), and a clear referral pathway to a DBS or focused-ultrasound centre when needed. Continuity over 10-20 years matters more than prestige — your neurologist should know your medication history and red-flag triggers in detail.
The first noticeable sign is usually a slight tremor of one hand or finger at rest, often the thumb rolling against the index finger, accompanied by reduced arm swing on the same side. Non-motor symptoms such as loss of smell, chronic constipation, depression, and acting out dreams during sleep often precede the tremor by 5-10 years and are increasingly recognised as the earliest signs.
How is Parkinson's disease diagnosed?▾▴
Parkinson's is diagnosed clinically by a neurologist based on the MDS 2015 Clinical Diagnostic Criteria — bradykinesia plus rest tremor or rigidity, with a clear response to levodopa and no atypical red flags. Brain MRI rules out mimics, and DaT-SPECT imaging helps when the picture is uncertain. There is no single blood test, though CSF alpha-synuclein assays are emerging.
Is Parkinson's disease hereditary?▾▴
Most Parkinson's disease is sporadic, but roughly 5-10% of cases have an identifiable monogenic cause. Mutations in LRRK2, GBA, SNCA, Parkin, PINK1, and DJ-1 raise risk. A first-degree relative with Parkinson's roughly doubles personal risk. Genetic testing is offered in young-onset disease, strong family history, or relevant ancestry.
What causes Parkinson's disease?▾▴
Parkinson's disease is caused by progressive loss of dopamine-producing neurons in the substantia nigra of the brain, together with abnormal accumulation of alpha-synuclein protein as Lewy bodies. Genetics, mitochondrial dysfunction, oxidative stress, pesticide exposure, head injury, and gut-brain pathology all contribute. The exact trigger remains unknown in most patients.
How fast does Parkinson's disease progress?▾▴
Progression is slow and variable. Most patients live with the disease for 15-20 years after diagnosis. Motor fluctuations and dyskinesias usually appear 5-10 years after starting levodopa. Recurrent falls develop on average around year 9-10, and dementia affects up to 80% of patients after 20 years. Tremor-dominant disease tends to progress more slowly than postural-instability subtype.
Is there a cure for Parkinson's disease?▾▴
There is currently no cure and no licensed disease-modifying treatment, but symptoms can be controlled effectively for many years. Levodopa, dopamine agonists, MAO-B inhibitors, deep brain stimulation, and focused-ultrasound thalamotomy all improve quality of life. Anti-alpha-synuclein antibodies such as prasinezumab are in Phase III trials and may slow progression in the future.
What is the best medication for Parkinson's disease?▾▴
Carbidopa-levodopa is the most effective medication for motor symptoms and is recommended as first-line therapy in most patients of any age once symptoms affect daily function. The PD MED trial showed it gives the best long-term quality of life. MAO-B inhibitors and dopamine agonists are alternatives in mild early disease where dyskinesia risk is the primary concern.
What is the life expectancy with Parkinson's disease?▾▴
With modern care, life expectancy is close to age-matched peers for the first 10-15 years after diagnosis, and the gap widens later mostly due to dementia, falls, and aspiration pneumonia. Average disease duration is 15-20 years. Younger age at onset and tremor-predominant subtype predict longer survival.
Can exercise slow Parkinson's disease?▾▴
Regular vigorous exercise improves motor function and quality of life and may modestly slow motor progression. The SPARX trial showed high-intensity treadmill training slowed MDS-UPDRS motor decline at 6 months. Tai chi reduces falls by about 50% versus stretching. A physiotherapist with Parkinson's experience should design a balanced aerobic, resistance, and balance program.
What is deep brain stimulation for Parkinson's disease?▾▴
Deep brain stimulation (DBS) is a surgical treatment in which electrodes are placed in the subthalamic nucleus or globus pallidus and connected to a pulse generator in the chest. It reduces motor fluctuations and dyskinesias in patients with advanced disease who still respond to levodopa. The landmark Deuschl 2006 trial showed clear superiority over best medical therapy.
Who is a good candidate for deep brain stimulation?▾▴
Good candidates have idiopathic Parkinson's disease with a clear levodopa response, disabling motor fluctuations or dyskinesias, intact cognition, no significant untreated depression or psychosis, and typically age under 70. Atypical parkinsonism, dementia, and uncontrolled psychiatric illness are exclusions. A movement-disorder neurologist and neurosurgeon assess suitability together.
Can Parkinson's disease cause dementia?▾▴
Yes. Parkinson's disease dementia develops in up to 80% of patients after 20 years of disease. Symptoms include slowed thinking, attention and executive problems, visual hallucinations, and memory difficulty. Rivastigmine has the strongest evidence for symptomatic treatment. When cognitive impairment begins within a year of motor onset, dementia with Lewy bodies is the more likely diagnosis.
What is the difference between Parkinson's disease and essential tremor?▾▴
Essential tremor produces a bilateral action tremor that appears when holding a posture or moving, often improves with alcohol, and runs in families. Parkinson's tremor is unilateral at onset, present at rest, disappears with voluntary movement, and is accompanied by slowness and rigidity. DaT-SPECT is normal in essential tremor and reduced in Parkinson's disease.
Can young people get Parkinson's disease?▾▴
Yes. About 10% of patients are diagnosed before age 50, which is called young-onset Parkinson's disease. Monogenic causes such as LRRK2, Parkin, PINK1, and GBA mutations are more common in this group. Disease progression is generally slower than in older-onset disease, but levodopa-induced dyskinesias often emerge sooner.
Does Parkinson's disease affect women differently than men?▾▴
Men develop Parkinson's disease 1.4-2.0 times more often than women, possibly due to a partially protective effect of estrogen. Women tend to be diagnosed slightly later, have more tremor-predominant disease, and report more non-motor symptoms such as depression and pain. Levodopa dosing may need to be adjusted because women weigh less on average.
What foods should I avoid with Parkinson's disease?▾▴
Large high-protein meals can blunt absorption of levodopa, so taking medication 30-45 minutes before or 1-2 hours after a protein-heavy meal is recommended. Excess alcohol, ultra-processed foods, and very high dairy intake in men are linked to higher Parkinson's risk in cohort studies. A Mediterranean-style diet is consistently associated with better outcomes.
Can stress make Parkinson's symptoms worse?▾▴
Yes. Stress, anxiety, fatigue, and poor sleep all transiently worsen tremor, rigidity, and gait freezing. Treating anxiety and depression, ensuring adequate sleep, and regular exercise reduce these fluctuations. Stress does not cause Parkinson's disease but can make existing symptoms more visible day to day.
Are dopamine agonists safe?▾▴
Dopamine agonists effectively control motor symptoms but cause impulse control disorders such as pathological gambling, hypersexuality, and compulsive shopping in 14-17% of users. Older patients are also more prone to hallucinations, sleep attacks, and leg swelling. Patients and partners should be counselled about these risks before starting and reviewed at each visit.
Can I drive with Parkinson's disease?▾▴
Many patients drive safely for years after diagnosis, but driving ability should be reviewed at diagnosis and at least annually. Motor fluctuations, dyskinesia, daytime sleepiness, hallucinations, and cognitive decline all impair driving safety. National medical-driving authorities require notification in most countries, and a formal on-road assessment is recommended at the first sign of concern.
What is REM sleep behavior disorder and how is it linked to Parkinson's?▾▴
REM sleep behavior disorder (RBD) is acting out vivid dreams during sleep with kicking, punching, or shouting, instead of the normal paralysis of REM sleep. Isolated RBD is the strongest known prodrome of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy — over 80% of patients with RBD develop one of these conditions within 14 years.
When should I see a neurologist for suspected Parkinson's?▾▴
See a neurologist promptly if you notice a persistent one-sided tremor at rest, unexplained slowness, stiffness, smaller handwriting, reduced arm swing, recurrent falls, or new acting out of dreams. Early specialist diagnosis confirms or excludes Parkinson's, rules out treatable mimics, and starts appropriate therapy before significant disability accumulates.
Rigidity with a 'cogwheel' or 'lead-pipe' quality felt on passive movement of the wrist or elbow, often accompanied by aching shoulder pain that can be misdiagnosed as frozen shoulder for months before tremor appears.
04Postural instability emerging after several years of disease, producing a stooped posture, festinating gait, and recurrent falls — a major driver of fracture and hospitalization in advanced disease.
05Gait freezing, in which the feet feel momentarily glued to the floor especially when starting to walk, turning, or passing through a doorway; freezing is a leading cause of falls and loses responsiveness to levodopa over time.
06Hypophonia and dysarthria, with a soft, monotone, slurred voice that the patient often perceives as normal while listeners struggle to hear — present in over 80% of patients within 5 years of diagnosis.
07Reduced sense of smell (hyposmia or anosmia), which precedes motor symptoms by 5-10 years in many patients and is now one of the most reliable prodromal markers.
08REM sleep behaviour disorder (RBD), in which the patient acts out vivid dreams with kicking, punching, or shouting; isolated RBD progresses to Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy in over 80% of cases within 14 years (Postuma 2019).
09Chronic constipation, often preceding motor symptoms by a decade — reflecting early alpha-synuclein pathology in the enteric nervous system.
10Mood and cognitive changes including depression in 40-50%, anxiety in 30-40%, apathy, executive dysfunction, and — in advanced disease — Parkinson's disease dementia affecting up to 80% of patients after 20 years.
early warning signs
•Loss or reduction in sense of smell several years before any movement symptom
•Acting out dreams during sleep with vocalizations or limb movements (REM sleep behaviour disorder)
•New-onset chronic constipation without a gastrointestinal explanation in middle age
•Subtle change in handwriting — letters becoming smaller and more cramped (micrographia) over months
•Reduced arm swing on one side, often noticed by family members in photos before the patient notices
● emergency signs
•Sudden severe rigidity, high fever, altered consciousness, and elevated creatine kinase — neuroleptic malignant-like syndrome from abrupt withdrawal of dopaminergic medication; medical emergency
•Acute confusion, visual hallucinations, and agitation in a patient on dopaminergic therapy, especially with infection or recent medication change — needs urgent evaluation for delirium, drug toxicity, or infection
•Recurrent falls with head injury or fracture — postural instability with anticoagulation raises bleed risk and warrants prompt assessment
•Sudden inability to swallow, drooling with choking on liquids, or aspiration pneumonia signs — dysphagia in advanced disease needs same-week speech and language review
•Suicidal thoughts in a patient with new-onset Parkinson's depression or after starting dopamine agonist therapy — urgent psychiatric assessment
Brain MRIExcludes structural mimics — vascular parkinsonism, normal-pressure hydrocephalus, brain tumour, Wilson's disease, and to a degree atypical parkinsonian syndromes that show characteristic atrophy patterns (hot-cross-bun sign in MSA, hummingbird sign in PSP).
03
DaT-SPECT (123I-FP-CIT / DaTscan)Functional dopamine-transporter imaging. Reduced striatal uptake supports a presynaptic dopaminergic deficit and helps differentiate Parkinson's from essential tremor, drug-induced parkinsonism, and psychogenic tremor when the clinical picture is uncertain. Does not differentiate Parkinson's from MSA or PSP.
04
Levodopa response trialA clear, sustained improvement of at least 30% on the MDS-UPDRS motor score with adequate dosing (often 600-1000 mg/day for 4-8 weeks) is one of the strongest supportive features in MDS 2015 criteria. Poor response argues for an atypical parkinsonian syndrome.
05
MIBG cardiac scintigraphyDetects post-ganglionic sympathetic denervation of the heart, which is reduced in Parkinson's disease but preserved in multiple system atrophy and essential tremor. Useful where DaT-SPECT cannot distinguish atypical parkinsonism.
06
Cerebrospinal fluid alpha-synuclein seed amplification assay (RT-QuIC)Detects misfolded alpha-synuclein in CSF with ~90% sensitivity and ~95% specificity in research and increasingly clinical settings. Distinguishes synucleinopathies (Parkinson's, MSA, dementia with Lewy bodies) from tauopathies (PSP, CBD).
07
Genetic testing (LRRK2, GBA, SNCA, Parkin, PINK1 panel)Recommended in young-onset disease (<50), strong family history, or relevant ancestry (Ashkenazi Jewish, North African Arab). Carrier status affects prognosis, family counselling, and eligibility for emerging genotype-specific trials.
Outlook
Parkinson's disease progresses slowly over years to decades. With modern medical, surgical, and rehabilitation care, life expectancy is close to that of age-matched peers for the first 10-15 years after diagnosis, and the gap widens mostly in late disease driven by dementia, falls, aspiration pneumonia, and frailty. Average disease duration from diagnosis to death is approximately 15-20 years, longer in young-onset and tremor-predominant subtypes and shorter in postural-instability gait-disorder and GBA-mutation carriers. Functional milestones used in counselling include time to motor fluctuations (median 5-7 years on levodopa), time to recurrent falls (median 9-10 years), and time to dementia (cumulative incidence ~25% at 10 years and up to 80% at 20 years). Predictors of faster decline include older age at onset, postural-instability gait-disorder subtype, GBA mutations, early autonomic dysfunction, and REM sleep behaviour disorder. Predictors of better outcome are tremor-dominant subtype, younger onset, strong levodopa response, sustained physical activity, and integrated specialist care.
risk factors
Age over 60non-modifiable
The single strongest risk factor. Incidence rises sharply after 60 and continues to climb until very late life; prevalence reaches roughly 4% by age 80.
Male sexnon-modifiable
Men are affected 1.4-2.0 times more often than women across most populations. Estrogen is thought to be partially neuroprotective; the gap narrows after menopause.
Family history and monogenic mutationsgenetic
First-degree relative with Parkinson's roughly doubles risk. GBA variants raise risk 5-fold and accelerate cognitive decline; LRRK2 G2019S is the most common dominant mutation worldwide and especially prevalent in Ashkenazi Jewish and North African Arab populations.
Pesticide and herbicide exposureenvironmental
Long-term exposure to rotenone, paraquat, and organochlorines raises risk roughly 1.5-2x in agricultural worker cohorts. Trichloroethylene contamination has been linked to clustered case excess in industrial communities.
Traumatic brain injury with loss of consciousnessenvironmental
A history of moderate-severe TBI is associated with roughly 1.5-fold increased risk decades later; repeated mild TBI also raises risk, supported by veteran and athlete cohorts.
Rural living and well-water consumptionenvironmental
Cohort studies consistently show 1.4-1.7x higher Parkinson's incidence among adults with prolonged rural residence and well-water use, likely a marker of agricultural chemical exposure.
REM sleep behaviour disordernon-modifiable
Isolated RBD converts to Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy in more than 80% of patients within 14 years (Postuma 2019) — the strongest known clinical prodrome.
Hyposmia (reduced sense of smell)non-modifiable
Identifies a roughly 2-3x higher risk over the following decade in population screening and is part of the MDS prodromal criteria.
Constipationnon-modifiable
Chronic constipation predates motor symptoms by 10-20 years in many patients and roughly doubles future Parkinson's incidence in the Honolulu-Asia Aging Study and other cohorts.
Tobacco non-use and low caffeine intakemodifiable
Cigarette smoking and regular coffee consumption are paradoxically associated with lower Parkinson's risk in dozens of cohorts. The protective signal is robust but the mechanism is unclear, and the cardiovascular and cancer harms of smoking far outweigh any protective effect. This is described for completeness, not as advice.
•Berries, leafy greens, and nuts — flavonoid intake is linked to slower motor progression in cohort data (Gao 2012)
•Distributed protein intake throughout the day, with most protein in the evening meal, in patients experiencing levodopa-protein interactions
foods to avoid
•Excessive saturated fat and ultra-processed foods, associated with higher Parkinson's risk in cohort studies
•Heavy dairy intake in men (>3 servings/day) — modestly associated with higher Parkinson's risk in the HPFS cohort
•Alcohol excess — disrupts sleep, worsens balance, and interacts with several Parkinson's medications
•Grapefruit juice with certain Parkinson's medications — check interactions with rotigotine and others
•Large high-protein meals immediately before a levodopa dose if motor response is unpredictable
06Impulse control disorders (pathological gambling, hypersexuality, compulsive shopping or eating) in 14-17% of patients on dopamine agonists — preventable with informed consent and dose review
07Depression and suicide risk — depression affects 40-50% of patients and is undertreated; suicide risk is roughly twice the general population in some studies
Compare →
Treat depression and anxiety actively — they often respond well to SSRIs and to structured exercise, and untreated depression accelerates functional decline
Daily management
01Take Parkinson's medications at the same times each day, set phone alarms, and never abruptly stop dopaminergic medication — withdrawal can precipitate a neuroleptic-malignant-like crisis
02Keep a simple on/off diary for at least 1-2 weeks before each neurology visit; this guides dose timing changes far better than verbal recall
03Carry a medication and emergency contact card, and update next of kin on which drugs must never be missed (including overnight in hospital)
04Plan the day around predictable on-times for tasks that require dexterity, balance, or driving
05Maintain a hydration and bowel routine — fibre, fluids, and movement keep constipation manageable and reduce levodopa absorption variability
06Attend an annual review with the multidisciplinary team — neurologist, Parkinson's nurse specialist, physiotherapist, occupational therapist, speech and language therapist
Exercise
Aim for 150 minutes per week of moderate-to-vigorous aerobic activity (treadmill, cycling, swimming), two sessions of resistance training, and daily balance and flexibility work (tai chi, yoga, dance). The SPARX trial showed high-intensity treadmill training at 80-85% maximum heart rate slowed motor progression at 6 months. Tai chi reduces falls in Parkinson's by roughly 50% versus stretching. Boxing-style training programs (Rock Steady Boxing and similar) improve balance and quality of life. Exercise prescription should be tailored by a physiotherapist with Parkinson's experience and adjusted as disease progresses.